Phase IIb Gastroparesis Data Devastate; Tranzyme Falls 76%
Shares of Tranzyme Pharma Inc. plunged on release of top-line results from the first of two Phase IIb trials of its gastroparesis candidate, TZP-102, showing that it did not meet its primary efficacy endpoint at either tested dose.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter